NCT00963755已完成不适用
Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
University of Lausanne Hospitals1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年8月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Sensitivity and specificity of FCH PET/CT, MR imaging, 3-D MR spectroscopy, and fusion PET/MR imaging for the intraprostatic localization of cancer in patients with radical prostatectomy as compared to histology as the gold standard
研究概览
简要总结
The purpose of this study is to demonstrate that realization of guided biopsies by multimodal imaging with 18F-fluorocholine PET / CT and MR Imaging/spectroscopy would allow to increase the rate of detection prostate cancer compared with the current approach and give an information about location and tumoral volume before surgery.:
详细描述
- To evaluate the utility of F-18-FCH-PET/CT and MR imaging with 3-D MR spectroscopy in detecting, localizing, and estimating the volume of initial primary prostate cancer as compared to the current standard work-up using TRUS-guided biopsy. All imaging findings will be correlated with "gold standard" step slice histological examination. The hypothesis is that the combination of noninvasive imaging will improve the preoperative work-up as compared to the current approach.
- To evaluate FCH-PET for the restaging of prostate cancer after biochemical relapse in a large patient cohort. This will run in parallel to the work-up of primary prostate cancer, as the FCH radiopharmaceutical will be available during the time of study at absolutely no cost to patients or CHUV. A number of studies have demonstrated the benefits of F-18-FCH-PET/CT for these patients and this indication is currently not reimbursed by Swiss obligatory health insurance providers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 80 Years（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age ≤ 80 years
- •Karnofsky index ≥ 80
- •First prostate biopsy
- •Presence of at least one of the following:
- •Total PSA 10 ng/mL
- •Total PSA 2.5-10 ng/mL with free-PSA <20% and/or PSA velocity 0.75 ng/mL/year
- •Suspicious hypoechoic lesion at TRUS and/or suspicious finding at digital rec¬tal examination
- •Informed signed consent.
排除标准
- •Impaired capacity to consent
- •Coexistence of clinically-proven prostate cancer
- •Neoadjuvant hormonal treatment (including 5-α reductase inhibitors)
- •Contraindications to surgery
- •Contraindications to MR Imaging (see below)
- •PROSTATE CANCER RELAPSE
- •Inclusion Criteria:
- •Age ≤ 90 years
- •Karnofsky index ≥ 80
- •Previous treatment for prostate cancer
- •No clinical recurrence based on standard work-up (abdominal / pelvic CT, MRI, and bone scintigraphy)
- •Biochemically proven relapse of prostate cancer (PSA > 0.2 ng/mL after prostatectomy, nadir PSA+2 ng/mL (Phoenix definition) or ≤ 3 successive rising PSA levels (ASTRO definition) after curative radiotherapy).
- •Informed signed consent.
- •Exclusion Criteria:
- •Coexistence of another clinically-proven cancer
- •Contraindications to surgery or radiation therapy treatment
结局指标
主要结局
Sensitivity and specificity of FCH PET/CT, MR imaging, 3-D MR spectroscopy, and fusion PET/MR imaging for the intraprostatic localization of cancer in patients with radical prostatectomy as compared to histology as the gold standard
时间窗: After prostatectomy (week 7-9 if Gleason score ≥ 8, week 7-15 if Gleason <8)
For prostate cancer patients with relapse: To determine the impact of FCH-PET imaging for localizing relapse patients in patients with biochemical failure as compared to the standard clinical workup
时间窗: After PET/CT, week 1-2
次要结局
- To determine if imaging allows for a reliable estimation of tumor volume, as these limits imply a significantly different prognosis in elderly patients (insignificant disease = volume <0.5 cm3 vs. significant disease ≥0.5 cm3)(After prostatectomy (week 7-9 if Gleason score ≥ 8, week 7-15 if Gleason <8))
- To determine the utility of dynamic PET imaging using 10 × 1 min acquisitions (0-9 min) as compared to a 5 min static acquisition starting 3 min and a delayed static whole-body acquisition (1 hour after radiotracer injection)(During PET/CT, week 1-2)
- To determine the impact of parametric PET/CT imaging based on dynamic PET acquisi¬tions with kinetic modeling(During PET/CT, week 1-2)
- For prostate cancer patients with relapse: To investigate the potential link between the overall accuracy of FCH and the serum androgen profile (total and free testosterone level) at the day of PET acquisition(After PET/CT, week 1-2)
- Impact of image-guided biopsies in obtaining adequate tissue samples for histological examination as compared to TRUS-guided extended systematic 12-core biopsies(After TRUS biopsies (week 3))
研究者
John O. Prior
Professor and Department Head
University of Lausanne Hospitals
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate CancerProstate CancerNCT01804231Lawson Health Research Institute22
撤回
不适用
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBMAstrocytoma, Grade IVGiant Cell GlioblastomaGlioblastoma MultiformeNCT00943462Centre hospitalier de l'Université de Montréal (CHUM)
已完成
不适用
The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid AdenomasParathyroid AdenomaHyperparathyroidismNCT04570033Military Institute od Medicine National Research Institute65
尚未招募
Unknown
Multimodal imaging study using Florzolotau PET and brain MRI for the patients with frontotemporal lobar degeneration and atypical ParkinsonismKCT0008805Gachon University Gil Medical Center120
已完成
1 期
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and BortezomibAdvanced CancerNCT01143779M.D. Anderson Cancer Center3